"BTI's Transcend platform is a huge financial incentive to the owner of the therapy because it could greatly extend the drug's exclusivity." (5/16/13) biOasis Technologies Inc. - The Life Sciences Report Interview with William Gregozeski Moreá>
"MSLP was growing very fast, and it had significant events that made it possible for us to raise $12M for it." (4/25/13) MusclePharm Corp. - The Life Sciences Report Interview with Richard Huebner Moreá>
"What's particularly exciting about VNRX is that it believes its technology is able to identify targeted cancers in stage 1 and stage 2." (4/25/13) VolitionRx Ltd. - The Life Sciences Report Interview with Dick Huebner Moreá>
Some companies with expected catalysts
Johnson & Johnson Merck & Co. Neuralstem Inc.
Top Investors and Analysts Use This Exclusive Report to Anticipate the Prospects of Medical and Biotech Stocks.
Now you can, too!
Access to The BioMed Tracker Report usually costs $2,000. For a limited time you can get access to the Report for FREE.
Biomedical stocks can soar depending on key catalysts and outcomes, such as FDA approval, regulatory changes, and clinical studies. The more accurately you can anticipate the results, the higher your profits.
We know that portfolio managers and analysts will pay big bucks for top-flight investment research. And for many investors and analysts the ultimate interactive biotech & pharmaceutical investment tool is the BioMedTracker Report -ľ, from Sagient Research:
- The BioMedTracker Outlook report is sorted by catalyst type, date and company, giving you quick, sortable access to exclusive information.
- The Report is part of a membership which usually costs $2,000 per year.
Right now, for a limited time, Sagient is offering free access to the current BioMedTracker Report to readers of Streetwise Reports.
"The Abstral acquisition has transformed GALE from a development biotech company into a commercial organization." (4/4/13) Galena Biopharma Inc. - The Life Sciences Report Interview with Grant Zeng Moreá>
"I believe the monoclonal antibody technology that SYN is working on for pertussis is especially interesting." (3/28/13) Synthetic Biologics Inc. - The Life Sciences Report Interview with Keith Markey Moreá>
"If phase 2b ASSURE trial results show a significant decrease in atherosclerotic plaque volume, it will be a huge win for RVX." (3/7/13) Resverlogix Corp. - The Life Sciences Report Interview with George Zavoico Moreá>